Please login to the form below
Bluebird Bio
This page shows the latest Bluebird Bio news and features for those working in and with pharma, biotech and healthcare.
BCMA in the spotlight as ASH abstracts drop
candidates. The publication of the ASH abstracts yesterday revels no fewer than 51 presentations involving BCMA, including a slew of CAR-T therapies from Bluebird Bio/Celgene, Juno/Celgene, Nanjing ... Bluebird/Celgene’s CAR-T bb2121 is currently
Latest news
-
EMA to review Bluebird’s blood disorder gene therapy
Bluebird Bio announced late last week that the European Medicines Agency has accepted its gene therapy LentiGlobin for accelerated review. ... medical officer, Bluebird Bio.
-
Orchard plans IPO as gene therapy pipeline advances
Orchard is playing catch-up in thalassaemia with Bluebird Bio, which is planning to file its LentiGlobin candidate in Europe before the end of this year, but getting PRIME status in
-
Regeneron and Bluebird sign $100m cell therapies deal
Big biotech’Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence in next-generation cell therapies. ... The collaboration with Regeneron complements Bluebird Bio’s growing
-
Ionis and Roche gain PRIME status for Huntingdon’s disease candidate
Other companies which have PRIME status include gene therapy specialists Bluebird Bio, who are expected to file their LentiGlobin therapy for beta thalassemia later this year.
-
Bluebird’s first gene therapy gets European fast track
Gene therapy company Bluebird Bio is on course to file its first product later this year, and has just been granted an accelerated review by the European Medicines Agency. ... Bluebird Bio: on the cusp of a gene therapy revolution (PME July/August
More from news
Approximately 7 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Bluebird Bio: on the cusp of a gene therapy revolution
Bluebird Bio: on the cusp of a gene therapy revolution. Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe. ... The next company to play its hand in this biotech-led transformation of
-
Deal Watch September 2016
The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 1, 695. Medigene /Bluebird bio. Licence. Development and
-
Pharma deals in May 2015
Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell
-
Deal Watch table for June 2014
208. Pregenen/ bluebird bio. Company acquisition. Gene editing technology platform. 156.
-
Pharma deals during March 2013
344. Bluebird bio/ Celgene Corporation. Option &licence. CAR T-cell therapy for oncology (platform).
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Celgene boosts CAR-T stake again with Bluebird Bio deal
Celgene boosts CAR-T stake again with Bluebird Bio deal. The US biotech could receive $70m in development milestones for the candidate. ... Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy
-
Proteostasis Therapeutics strengthens leadership team
James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
-
Senior Medical Writer
-
Competitive Salary
-
Associate Medical Director
-
Highly Competitive
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Associate Director
-
£75, 000-90, 000
-
Medical Writers
-
Competitive Salary and Benefits
Subscribe to our email news alerts
- Golin opens office in Malaysia
- Synergy Vision to introduce four-day working week
- SWITCHED ONcology. Caregivers Focus Group Highlights. www.switchedoncology.com
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Life Sciences 4.0 - Antony Rawlins
- What is blockchain? - Richard Springham
Latest intelligence
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
- World Diabetes Day: Interaction and impact of diabetes on mental health
- For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
Quick links
Infographics
